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Dendritic cells (DCs) are antigen-presenting cells that drive immune responses and tolerance and are divided
in different subsets: myeloid DCs (mDCs: lineage; HLA-DRþ, 11cþ), plasmacytoid dendritic cells (pDCs:
HLA-DRþ, CD123þ), and monocyte-derived DCs (moDC: lineage, 11cþ, 16þ). After hematopoietic stem cell
transplantation (HSCT), low DC counts in the recipients’ peripheral blood (PB) have been associated with
worse outcomes, but the relevance of DC graft content remains unclear, and there are few data in the setting
of unrelated donor HSCT. We evaluated the DC graft content and monitored DC recovery in PB from 111 HSCT
recipients (median age, 17 years; range 1 to 74), who received bone marrow (46%), umbilical cord blood (32%),
or PB (22%) from unrelated (81%) or related donors (19%). In 86 patients with sustained allogeneic recovery,
patients with higher counts of all DC subsets (pDC, mDC, and moDC) 3 weeks after engraftment had lower
incidence of nonrelapse mortality (NMR) and acute graft-versus-host disease (aGVHD) and better survival.
pDC counts were associated with more striking results: patients with higher pDC counts had much lower
incidences of NRM (3% versus 47%, P < .0001), lower incidence of aGVHD (24% versus 67%, P < .0001), and
better overall survival (92% versus 45%, P < .0001). In contrast, higher pDC counts in the graft was associated
with an increased risk of aGVHD (55% versus 26%, P ¼ .02). Our results indicate that DC counts are closely
correlated with HSCT outcomes and warrant further prospective evaluation and possible early therapeutic
interventions to ameliorate severe aGVHD and decrease mortality.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION the incidence of graft-versus-host disease (GVHD), infection,
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ty for Blood and Marrow Transplantation.relapse, and mortality are still relatively high [1]. After
transplantation, a cascade of complex and poorly understood
events occur, which involves interactions of transferred and
newly formed cells of donor origin with host cells. The type
and intensity of these interactions will ultimately lead to
different grades of acute GVHD (aGVHD), graft-versus-tumor
(GVT) effects, and risk of infections, directly contributing to
the success of the treatment [1].
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that act mainly through the activation or inhibition of T cells,
leading to activation of Immune responses or tolerance [2-5],
depending on their subtype and maturation status [6-8]. DCs
represent a heterogeneous population of cells consisting of
distinct subsets: myeloid (or conventional) DCs (mDC) and
plasmacytoid DCs (pDC). Although mDCs exhibit proin-
ﬂammatory responses leading to proliferation and activation
of TCD8þ cells to become cytotoxic, pDCs are involved on
peripheral tolerance, viral host defense, and interferon pro-
duction [2,3,9,10]. Circulating macrophages may also differ-
entiate into DCs, being a potent allostimulatory cell subtype,
referred to as monocyte-derived DCs, 16þ/14 monocytes
(moDC), or inﬂammatory DCs [11].
After HSCT, DC recovery in peripheral blood (PB) is rela-
tively slow, and normal counts are only achieved after 3
months or later, depending on the recipients’ clinical con-
dition [12-14]. At such early phases (ﬁrst 3 months), studies
have shown that lower DC counts are associated with a
higher presence of aGVHD and a poorer overall survival (OS),
although their impact on disease relapse remains contro-
versial [15-17]. Besides, some studies addressed the clinical
relevance of DC content in the graft with conﬂicting results
[15,18-20]. To date, only a few studies have simultaneously
analyzed the pDC graft content, the kinetics of DC recovery,
and the HSCT outcomes in the same patient population. In
addition, most of these studies only included patients
receiving grafts from matched related donors and deter-
mined DC counts in ﬁxed time points, independent of day of
engraftment or stem cell source.
In the present study, we analyzed DC recovery after
transplantation and DC content in the graft in patients
receiving allogeneic HSCT, mainly from unrelated donors.
Using a novel strategy, considering the day of engraftment as
baseline for DC recovery analyses, we investigated the as-
sociation between the kinetics of DC recovery and the main
HSCT outcomes.
PATIENTS AND METHODS
Patients from 4 transplantation centers were included. Each individual
provided written informed consent to participate according to the Decla-
ration of Helsinki. The study was approved by each center’s local ethics
committee.
PB samples were obtained at predeﬁned time points as follows: before
the conditioning regimen was administered, at engraftment, at
days þ3, þ7, þ14 and þ21 after engraftment, and at days þ60, þ100
and þ180 after transplantation. This strategy was used to normalize pDC
recovery considering the engraftment date as the baseline in all patients, as
engraftment is known to be delayed in umbilical cord blood (UCB) recipients
compared with bone marrow (BM) and PB recipients. Graft samples were
also analyzed when available (30 BM, 17 UCB, 13 PB).
Cells Populations Identiﬁcation by Flow Cytometry
T CD4 lymphocytes, T CD8 lymphocytes, pDC (lineage, HLA-DR high,
CD123 high), mDCs (lineage, CD11cþ, CD16), and moDCs (lineage,
CD11cþ, CD16þ) were quantiﬁed by 4-color ﬂow cytometry. Brieﬂy, fresh
EDTA-anticoagulated PB or graft samples (mobilized PB, BM, or UCB) were
stained with a combination of ﬂuorochrome-conjugated monoclonal anti-
bodies (CD3 APC, CD4 FITC, CD8 PE, CD11c APC, CD34 APC, CD45 Per-CP,
CD123 PE HLA-DR FITC, [Becton Dickinson, San Jose, CA], CD16 PE [Immu-
notech] and Dendritic exclusion kit [Cytognos, Salamanca, Spain]). Samples
were processed within 24 hours, and data were acquired for 105 leuko-
cytes/tube using the FACSCalibur ﬂow cytometer (BD Biosciences). The
Inﬁnicity software (Cytognos) was used for data analysis. All analyses were
performed in a central laboratory at UNIFESP by 2 independent investigators
(Figure 1).
Statistical Analyses
For the analyses of the main clinical outcomes, patients were divided
into 2 groups on the basis of different absolute cell count cutoffs for eachtime point. Using the Mann-Whitney test, we analyzed all quartiles of cell
counts at each time point, and the median values of the absolute counts
were used to separate 2 groups (high and low counts), as they showed the
best correlation with the studied outcomes: aGVHD and chronic GVHD
(cGVHD), diagnosed and graded according to published criteria [21,22],
relapse or progression, nonrelapse-related mortality (NRM), progression-
free survival (PFS), and OS.
Probabilities of PFS and OS were calculated using the Kaplan-Meier
estimator and compared using the log-rank test, and cumulative incidence
rates were calculated for aGVHD and cGVHD as well as relapse, with death
being considered a competing event. Ninety-ﬁve percent conﬁdence in-
tervals (CIs) were estimated using the Greenwood formula. Adjusted prob-
abilities for outcomes after transplantation were estimated using the Cox
proportional hazards method. The association between cells counts and
HSCT outcomes was investigated in the ﬁnal multivariate models adjusting
for patient-, disease-, and transplantation-related variables with an impact
(P < .01) in the univariate analyses or if they had been reported to be clin-
ically relevant. First-order interactions between DC counts and each variable
of interest were examined. The results are presented as relative risks of
failure (adverse prognostic factors versus good prognostic factors), with the
95% CIs and 2-sided P values. SPSS, version 20.0 (SPSS Inc., Chicago, IL), was
used for all statistical analyses except for the cumulative incidence analyses,
which were performed using S-PLUS software (TIBCO Software Inc., Palo
Alto, CA).
RESULTS
BetweenMay 2010 and November 2012,111 patients (65%
male; median age, 17 years; range, 1 to 74) from 4 trans-
plantation centers were included. Chimerism data were
evaluated during the ﬁrst 3 months after HSCT. Full donor
chimerism was deﬁned as the presence of more than 95% of
cells of donor origin. Patients who did not achieve neutrophil
recovery or had neutrophil recovery but not full donor
chimerism (n ¼ 13), who died 1 week or earlier after
engraftment (n ¼ 10), or who were lost from follow-up (n ¼
2) were excluded from the analyses. There were no signiﬁ-
cant differences between the included and excluded patients
groups regarding any of the clinical features (data not
shown). Analyzed patient characteristics are presented in
Table 1. Conditioning regimen, graft source, GVHD prophy-
laxis, time to transplantation, and all other clinical decisions
were made according to each center’s guidelines.
The most common underlying diagnosis was acute leu-
kemia (70%). Patients received stem cells from BM (48%), UCB
(29%), or PB (23%), derived from related (19%) or unrelated
donors (81%). Most patients received a myeloablative con-
ditioning regimen (62%), and one half of them (51%) received
total body irradiation. T cell depletion with antithymocyte
globulin was used in 37% of patients. Median follow-up was
24 months (range, 4 to 47).
Kinetics of DC Recovery
As expected, the median total nucleated cell (TNC) counts
were almost 10-fold higher in BM and PB samples (4.43108
TNC/kg) compared with UCB samples (.56  108 TNC/kg).
Similarly, DC counts were also approximately 10-fold higher
in BM/PB, although the percentages were comparable among
all stem cell sources (.19% in BM/PB versus .20% in UCB).
However, no signiﬁcant differences were noted regarding the
kinetics of pDC, mDC, or moDC recovery after HSCTaccording
to the type of stem cell sources used, except for slightly lower
pDC counts at engraftment and at day þ3 after engraftment
and lower mDCs counts during the ﬁrst 2 weeks in UCB re-
cipients compared with BM/PB recipients. pDC and mDC
counts remained relatively stable during the ﬁrst 3 weeks
after engraftment and started to increase at day þ60 until
day þ100 in both patient groups, whereas the moDC count
was stable and comparable to normal ranges very soon after
engraftment, at day þ3.
Figure 1. Flow cytometry identiﬁcation of peripheral blood dendritic cells (DCs). As shown, plasmacytoid DCs (pDCs)(____) typically show low internal complexity (A)
and high expression of both CD123 and HLA-DR (B). Basophils are shown as a positive internal control for CD123 staining, but they are HLA-DR negative. Myeloid DCs
(mDC) and monocyte derived DCs (moDC) have high expression of HLA-DR and CD11c (C), are negative for lineage markers, and have distinct expression of CD16 (D).
M.V. Gonçalves et al. / Biol Blood Marrow Transplant 21 (2015) 1223e1229 1225DC recovery was not affected by any of the pre-
transplantation characteristics that were investigated (ie,
age, gender, conditioning regimen, use of total body irradi-
ation or T cell depletion, and GVHD prophylaxis). Similarly, it
was not affected by any of the host pre-HSCT subpopulations
counts.
As seen in other studies on T cell recovery, BM and PB
recipients presented a faster T cell recovery than UCB re-
cipients, mainly due to fast elevation of T CD8, showing an
early inversion of the CD4 to CD8 ratio.DC Counts and NRM
Cumulative incidence of NRM was 30% at 1 year. Patients
with lower DC counts after engraftment had a much higher
risk of NRM than patients with higher DC counts (Table 2).
The strongest association was noted for the pDC counts at
day þ21 after engraftment: NRM was 47% among thepatients with lower counts (<1.1 cells/mL) and only 3% in
patients with higher counts (P< .0001, Figure 2). Of note, in a
multivariate analysis, pDC counts < 1.1 cells/mL at day þ21
after engraftment was a powerful independent predictor of
higher NRM (hazard ratio [HR], 16.67; 95% CI, 2.07 to 142.86)
(Table 3) and the same was observed for pDC counts at day 7
and 14 after engraftment. In contrast, NRM was not affected
by the pDC counts in the graft.
As for pDC, moDC andmDC counts on the ﬁrst weeks after
engraftment also showed signiﬁcant correlationwith NRM in
univariate analyses. However in a multivariate analysis, mDC
remained signiﬁcant only at day 14 and moDC only at day 60
(Table 3).DC Counts and GVHD
The cumulative incidence of grade II to IV aGVHD at
day þ100 was 43% with a median time to aGVHD of 31 days
Table 1
Patient and Disease Characteristics
Characteristic Value
Patients, n 86
Age at transplantation, median (range), yr 18 (1-74)
Male sex 54 (63)
Diagnoses
Acute myeloid leukemia 32 (37)
Acute lymphoid leukemia 28 (33)
MDS/MPN 13 (15)
Severe aplastic anemia 7 (8)
Others 6 (7)
Disease activity (malignant diseases, n ¼ 75)
Acute leukemia or lymphoma in complete remission,
CML in chronic phase, MDS, MPN
60 (80)
Acute leukemia  third remission or with active disease
(relapse or progression)
15 (20)
Stem cell source
BM 41 (48)
UCB 25 (29)
PB 20 (23)
Donor
Unrelated 70 (81)
Related 16 (19)
Matched HLA (BM and PB)
Matched 42 (69)
Mismatched 14 (23)
Haploidentical 5 (8)
Matched HLA (cord blood)
Single
No or 1 incompatibilities 7 (61)
Two incompatibilities 5 (39)
Double
No or 1 incompatibilities per unit 3 (22)
At least 1 unit  2 incompatibilities 10 (78)
Reduced-intensity conditioning regimen 33 (38)
Total body irradiation 44 (51)
In vivo T cell depletion (antithymocyte globulin) 32 (37)
GVHD prophylaxis
Cyclosporine or tacrolimus þ MMF 36 (42)
Cyclosporine or tacrolimus þ MTX 27 (31)
Cyclosporine or tacrolimus  prednisone 15 (17)
Cyclosporine or tacrolimus þ MMFþ post-transplantation
cyclophosphamide
8 (9)
Follow up, median (range), mo 24 (4-47)
MDS indicates myelodysplastic syndrome; MPN, myeloproliferative
neoplasm; CML, chronic myelogenous leukemia; MMF, mofetil mycophe-
nolate; MTX, methotrexate.
Data presented are n (%) unless otherwise indicated.
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engraftment had a much higher incidence of aGVHD than
patients with higher pDC counts (Table 2), especially at
days þ21 and þ60 after engraftment (67% versus 24% and
73% versus 30%, respectively) (Table 2, Figure 3). Multivariate
analyses conﬁrmed the independent predictive value of
lower pDC counts at days 14, 21, and 60 after engraftment for
higher risk aGVHD (day þ21: HR, 3.31; 95% CI, 1.45 to 7.58)
(Table 3).
Conversely, patients receiving a higher percentage of pDC
in their grafts (.20% of TNC) had a signiﬁcantly higher
incidence of aGVHD at day þ100 after HSCT than those with
lower counts (55% versus 26%, P ¼ .02) (Table 2) and this
association remained signiﬁcant in the multivariate analysis
(HR, 2.98; 95% CI, 1.10 to 8.02) (Table 3).
Lower counts of mDC and moDC were also related to
higher incidence of aGVHD, and this relation was conﬁrmed
in multivariate analyses at days 21 and 60 (Table 3).
A cumulative incidence of cGVHD of 52% was observed 1
year after engraftment. Similar to NRM and aGVHD, lower
pDC counts at dayþ21 after engraftment was correlatedwith
a higher risk of cGVHD: 83 versus 38% (P ¼ .008) (Table 2).However, in a multivariate analysis, no independent pre-
dictive value of the pDC counts in cGVHD was observed. No
associationwas found between occurrence of cGVHD and the
pDC counts in the graft, mDC and moDC (Table 2).
DC Counts and Disease Relapse
Of the 86 evaluable patients, 76 hadmalignant underlying
diseases, with a cumulative incidence of relapse or progres-
sion at 1 year of 22%. Neither pDC, moDC, mDC, nor T cells at
any time point after transplantation had a signiﬁcant impact
on relapse or progression. The only signiﬁcant factor that
inﬂuenced relapse on multivariate analyses was advanced
stage of the disease (HR, 5.19; 95% CI, 1.21 to 22.31).
DC Counts and Survival
OS was 62% at 1 year. During follow-up, there were 36
deaths: 10 related to disease relapse and 26 attributable to
transplantation-related events. Eight died from aGVHD
complications, 16 from infection without clinically relevant
GVHD, 1 from cardiac arrhythmia, and 1 from secondary
acute leukemia. Most patients died in the ﬁrst 3 months after
transplantation. Patients with higher pDC counts at day þ21
after engraftment and at day þ60 had a much higher prob-
ability of survival (Table 3): 92% versus 45% (P < .0001)
(Table 2, Figure 4) and 93% versus 42% (P ¼ .001) (Table 2),
respectively. Lower pDC counts at day þ21 and day þ60 after
engraftment remained a statistically independent predictive
factor for higher OS in the multivariate analyses (at day þ21:
HR, 6.85; 95% CI, 1.92 to 24.39; Table 3; at day þ60: HR, 6.43;
95% CI, 1.68 to 24.66). In contrast, OS was not affected by the
pDC counts in the graft.
Also, mDC and moDC high counts positively correlated
with OS. However, whereas moDC counts remained signiﬁ-
cant only at dayþ60 after multivariate analyses, higher mDC
counts were associated with higher OS at days þ14 (90%
versus 44%, P < .001) (Table 3), day þ21 (84% versus 52%, P ¼
.001) (Table 3) and þ60 (90% versus 58%, P ¼ .02) (Table 3),
remaining signiﬁcant in a multivariate analysis (at day þ21,
HR: 4.31; 95% CI, 1.70 to 10.97; Table 3; at dayþ60: HR,10.20;
95% CI, 2.24 to 46.48). T cells subpopulations had no impact
on OS.
DISCUSSION
In this multicenter prospective study, we showed that low
DC counts, especially pDC counts, after engraftment are
stronglyassociatedwith poorer prognosis, reﬂected byhigher
NRM, greater incidence of acute GVHD, and shorter survival,
in a cohort composed of patients receiving allogeneic trans-
plantation, mostly from unrelated donors. The time point
associated with the strongest association for all analyzed
outcomes was day þ21 (3 weeks after engraftment).
Our results are partially consistent with previously pub-
lished series of patients receiving transplants mostly from
related donors [15-17,23] and with a few small series of
patients receiving transplants from unrelated donors
[13,14,24-26]. In these studies, low DC counts after HSCT
were associated with poorer survival, higher incidence of
aGVHD, and higher rate of relapse, in some series. In our
study, we did not ﬁnd any association with DC counts and
relapse. Therefore, the lower OS observed in patients with
low DC counts reﬂects higher mortality from
transplantation-related causes. All DCs had a signiﬁcant as-
sociation with outcomes, but pDCs were the subset with the
most consistent association with both aGVHD and, more
strikingly, NRM.
Table 2
Univariate Analyses of the Association of Dendritic Cell Counts and HSCT Outcomes
Outcome NRM at 1 Year (%) aGVHD at 100 Days (%) cGVHD at 1 Year (%) OS at 1 Year (%)
Overall 30 43 52 62
n* Cutoffy
(cell/mL)
High Low P Value High Low P Value High Low P Value High Low P Value
pDC 14 84 .91 16 33 NS 27 66 .04 52 40 NS 70 55 NS
pDC 21 84 1.1 3 47 <.0001 24 67 <.0001 38 71 .008 92 45 <.0001
pDC 60 73 1.7 4 37 .004 30 73 <.0001 43 65 .06 93 49 .001
mDC 14 84 3 3 45 .001 38 55 NS 40 57 NS 90 44 <.001
mDC 21 84 2.5 15 34 .04 27 62 .003 45 67 NS 84 52 .001
mDC 60 73 4.5 10 29 .04 31 70 .003 50 57 NS 90 58 .02
moDC 14 84 50 17 35 NS 30 63 .007 40 58 NS 73 53 NS
moDC 21 84 50 14 45 .04 30 60 .006 45 73 NS 83 45 .01
moDC 60 73 30 4 37 .005 37 63 .03 53 50 NS 96 50 <.001
pDC graft 60 .2% TNC 22 33 NS 55 2 .02 37 42 NS 58 57 NS
NS indicates not signiﬁcant (P > .05).
Numbers 14, 21, and 60 after cell populations refer to day after engraftment. High and Low refer to patients with cell counts above or below the cutoff.
* n refers to number of patients available to analyze.
y Cutoff values measured in cells/mL, except for pDC graft content, measured in percentage of total TNC.
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which the analysis of DC recovery was normalized at the day
of engraftment, considering it baseline for all patients. All
previously published studies [13-17,23-26] used ﬁxed time
points based on the day of transplantation (day 0), inde-
pendently of stem cell source or CD34þ cell dose. Based on
the current knowledge of immune reconstitution kinetics,
the use of a ﬁxed time point, such as 1 month after HSCT,
could lead to the comparison of patients at very different
moments in the hematopoietic reconstitution phenomena,
especially considering the inclusion of UCB transplant re-
cipients that usually engraft later than recipients of other
stem cell sources [27]. Besides, as we performed a weekly
monitoring of DC counts, we could demonstrate the steps of
DC reconstitution more closely than previously published
series and determine that the ﬁrst 2 and 3 weeks after
engraftment were the most closely related to the outcomes.
DC counts were not affected by the pretransplantation
patient characteristics (eg, age, conditioning regimen, T cell
depletion, or GVHD prophylaxis) or by DC counts in the graft.
The lack of correlation between DC counts in the graft and DCFigure 2. Cumulative incidence of nonrelapseerelated mortality for patients
with high (____) and low (...) plasmacytoid dendritic cells counts (using a
cutoff of 1 pDC/mL) measured 21 days after engraftment.recovery in the PB after HSCT conﬁrms previously published
data [15,16,24]. We also demonstrated that despite receiving
grafts with 10-fold fewer pDCs, once engraftment is estab-
lished, UCB transplant recipients presented DC recovery rates
that were comparable to the rates of those who received a
transplant from other sources. Also, although the number of
patients included does not allow subgroup analyses, multi-
variate analyses failed to demonstrated impact of graft
source on outcomes. Based on these results, one could
speculate that circulating DCs are newly formed and repre-
sent progeny of the donor stem cells rather than an oligo-
clonal expansion of transferred pDCs from the graft or host
circulating DCs. Chimerism studies of DCs, and not only of
the total mononucleated cells as performed in the present
study, could help to clarify this aspect.
Whether a low number of DCs after engraftment is
directly related to worse outcomes or if it is just a surrogate
marker for inadequate immune recovery remains unknown.
It remains to be determined whether pDC counts in the PB
reﬂect lower pDC production or an increased pDC migration
to tissues affected by infections and/or GVHD. Initial studies
failed to demonstrate increased DCs in skin biopsies from
patients with aGVHD [13,15,28], whereas in a more recent
cohort, pDC were increased in the intestinal mucosa of pa-
tients with aGVHD [29]. Besides, as steroids have been
shown to decrease the number of circulating pDCs, one
might speculate that steroids used to treat aGVHD may also
be the cause of lower DC counts after transplantation.
However, in our series, as well as in other previous studies
showing similar results, low pDC counts were reported
several days before the onset of aGVHD inmany patients and,
therefore, before the onset of steroid therapy [12,30,31].
Indeed, the explanation for the strong power of DC counts
in predicting outcomes after transplantation is still under
debate. DCs are expected to play a central role in the immune
reconstitution after transplantation. If there is an absolute
decrease on total body host DCs, one could expect that pa-
tients would be more susceptible to infections because of
ineffective antigen presentation and cytokine secretion. In
fact, in our series, as well as in another series with 79 sub-
jects, lower DC counts were associated with higher mortality
due to infectious complications [16]. Indeed, activated DCs
have strong antigen-presenting properties and are of
extreme importance to protect against virus (pDC) and bac-
teria (mDCs and moDCs) proliferation, whereas steady-state
Table 3
Multivariate Analysis of Prognostic Factors for Main Outcomes after
Transplantation
Outcome P Value HR 95% CI
NRM
<1.1 pDC/mL at day þ21 .008 16.67 2.07 142.86
Cord blood transplantation NS 3.24 .49 21.65
T cell depletion NS .42 .08 2.09
MMF prophylaxis NS .31 .05 2.03
<2.5 mDC/mL at day þ14 .006 18.18 2.31 142.86
Cord blood transplantation NS 1.22 .26 5.71
T cell depletion NS .57 .19 2.43
MMF prophylaxis NS .31 .06 1.51
<30 moDC/mL at day þ60 .017 13.89 1.59 125
Cord blood transplantation NS 3.59 .21 60.97
T cell depletion NS .10 .01 1.04
MMF prophylaxis NS .55 .03 9.04
aGVHD (at day þ100 after transplantation)
<1.1 pDC/mL at day þ21 .005 3.31 1.45 7.58
Age >17 yr .08 1.94 .91 4.11
T cell depletion NS .92 .39 2.18
MMF prophylaxis NS .68 .33 1.41
<3 mDC/mL at day þ21 .016 2.67 1.20 5.92
Age >17 yr .05 1.94 .99 4.42
T cell depletion NS .92 .35 1.93
MMF prophylaxis NS .68 .30 1.29
<50 moDC/mL at day þ21 .03 2.28 1.09 4.83
Age >17 yr .06 2.06 .97 4.32
T cell depletion NS .70 .31 1.60
MMF prophylaxis NS .66 .32 1.37
Graft pDC > .2% TNC .01 2.98 1.10 8.02
UCB transplantation .07 2.46 .93 6.54
T cell depletion .08 .40 .15 1.11
Total body irradiation .07 2.38 .94 6.04
cGVHD
<1.1 pDC/mL at day þ21 NS 2.15 .87 5.31
Age >17 yr NS 1.72 .73 4.06
T cell depletion NS .53 .19 1.49
MMF prophylaxis NS .74 .32 1.75
OS (at 1 yr)
<3.0 mDC/mL at day þ21 .002 4.31 1.70 10.97
Cord blood transplantation NS .92 .25 3.37
T cell depletion NS .54 .19 1.56
MMF prophylaxis NS .48 .13 1.71
<1.1 pDC/mL at day þ21 .003 6.85 1.92 24.39
Cord blood transplantation NS 1.59 .37 6.87
T cell depletion NS .44 .12 1.59
MMF prophylaxis NS .54 .13 2.18
<30 moDC/mL at day þ60 .002 28.57 3.39 250.0
Cord blood transplantation NS 1.35 .21 8.56
T cell depletion .018 .14 .03 .71
MMF prophylaxis NS 1.67 .29 9.39
Figure 3. Cumulative incidence of acute GVHD for patients with high (_____)
and low (...) plasmacytoid dendritic cells counts at day þ21 after
engraftment.
Figure 4. Overall survival for patients with high (_____) versus low (...)
plasmacytoid dendritic cells counts at day þ21 after engraftment.
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showed that moDC, differently from monocytes, rapidly re-
covers immune properties after autologous transplantation
and may contribute to infections control [32]. Only 1 study
before our series analyzed moDC after allogeneic HSCT,
having observed higher NRM, and higher relapse rates in
patients with lower moDC counts [16].
Previous studies have analyzed the association of DCs
with the complex pathophysiology of GVHD with contro-
versial results: some studies in mice have shown that pDC or
mDCs may initiate aGVHD whereas others have shown that
pDC may protect against aGVHD [33-35]. In the clinical
setting, all series, including ours, showed that a low DC
counts in the PB after transplantation are consistently asso-
ciated with a higher incidence of aGVHD both in adults and
in children [13,15,16,24,36]. In our series, we observed thatpDC counts in the graft had an opposite effect on GVHD to
that of pDC counts in the PB. Although this association was
less signiﬁcant, low pDC counts in the graft were associated
with a slightly lower risk of aGVHD. Previously published
series reported no impact of graft pDC counts on the inci-
dence of aGVHD [15,18,20], although they did not include
cases of UCB recipients and only a few cases of non-
myeloablative conditioning regimens. Studies with more
homogeneous cohorts are needed to better elucidate the
effect of DC graft content on clinical outcomes.
As a multicenter noninterventional HSCT study, our re-
sults, although very signiﬁcant, should be interpreted with
caution. HSCT procedures, conditioning regimens, and GVHD
prophylaxis signiﬁcantly differed between centers, as did the
stem cell sources. However, despite the heterogeneity of the
population included regarding age, disease, donor, stem cell
source, HLA matching, conditioning regimen, and GVHD
prophylaxis, none of the patient- or transplantation-related
variables affected DC recovery. Besides, none of these
M.V. Gonçalves et al. / Biol Blood Marrow Transplant 21 (2015) 1223e1229 1229variables inﬂuenced the association between DC counts and
patient outcomes, as conﬁrmed in a multivariate analysis.
In summary, low DC counts, especially low pDC counts,
observed in the ﬁrst weeks after engraftment are associated
with higher incidence of acute GVHD and mortality in allo-
geneic HSCT recipients. Our data support the critical rele-
vance of DC recovery in the HSCT setting, independent of
other clinical and biological variables. Determining DC
counts after transplantation could further support the
identiﬁcation of patient at higher risk of GVHD and mortality
and could warrant prospective evaluation and possible early
therapeutic interventions. A better understanding of the role
of DCs in the recovery of immunity after HSCT and the
complex interactions of DCs with infective agents and host
antigens requires further investigation.
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